EVAX

TentativeAI MemoPost-earnings T+1

Evaxion A/S

As of 2026-08-21/Post-earnings T+1/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-21 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

EVX-01 three-year phase 2 data at ESMO • 2026-10-31

Base target: $3 / p=55% prob

Biggest risk

The company remains pre-commercial with no Q2 revenue, a $3.7 million quarterly net loss, $14.0 million of cash, and continued dependence on capital markets or partnerships. EVX-01 is a binary clinical readout, while EVX-04 and EVX-05 remain earlier-stage programs. No post-print analyst revisions or target changes are available.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

The post-earnings update adds tangible forward hooks: EVX-01 three-year data is scheduled for ESMO in October, EVX-04 and EVX-05 expand the oncology pipeline, new EVX-V1 data support platform breadth, and management maintains runway into the second half of 2027 [#IR-2026-08-20][#SEC-6K-2026-08-20].

Research note

Recommendation

—

Confidence

medium

As of

2026-08-21

Base target

p=55%

Bull target

p=20%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q2 follow-up is financially mixed but runway remains intact
Potential platform or pipeline partnership
The post-earnings update adds tangible forward hooks: EVX-01 three-year data is scheduled for ESMO in October, EVX-04 and EVX-05 expand the oncology pipeline, new EVX-V1 data support platform breadth, and management maintains runway into the second half of 2027 [#IR-2026-08-20][#SEC-6K-2026-08-20].

BearKey bullets

Cash declined to $14.0 million at June 30, 2026 from $23.2 million at December 31, 2025, and the company may need additional capital before commercialization [#SEC-6K-2026-08-20].
Coverage is low, peer comparability is weak, and no analyst estimate or revision tape is available.
EVX-01 three-year data may fail to demonstrate durable benefit, and future development is dependent on clinical, regulatory, manufacturing, and partnering execution.

WatchKey bullets

EVX-01 three-year phase 2 data at ESMO

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $3 (p=55%)

Target spread vs base: +62% / -47%

Scenario probabilities

Bull Target: $6 (p=20%)Base Target: $3 (p=55%)Bear Target: $2 (p=25%)

Commentary

The official Q2 update was modestly constructive on runway and pipeline progress but not a conventional earnings beat: revenue remained zero and analyst consensus data are unavailable. A live market snapshot showed the stock at $3.28, up about 3.2% on August 21, suggesting a positive but still limited initial reaction. With low coverage, no revision data, and binary clinical risk, this remains a cautious monitoring setup.

As of 2026-08-21 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q2 follow-up is financially mixed but runway remains intact
Potential platform or pipeline partnership

Scenarios

Bull Target (Scenario probability)

$6 / p=20% prob

Base Target (Scenario probability)

$3 / p=55% prob

Bear Target (Scenario probability)

$2 / p=25% prob

Analysis 2026-08-21 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-10-31
EVX-01 three-year phase 2 data at ESMO
Evaxion expects to present three-year clinical efficacy and durability data for personalized melanoma vaccine EVX-01 at the ESMO Congress in October 2026. The readout is the clearest near-term value-setting event for the micro-cap biotech [#IR-2026-08-20].
Prob 65.00% • Move 28.00% • Priced-in 45.00%
EVENT2026-12-31
EVX-04 phase 1 regulatory filing target
Company materials identify a second-half 2026 regulatory filing target for an EVX-04 phase 1 trial in acute myeloid leukemia, creating an execution checkpoint beyond EVX-01 [#IR-2026-08-20].
Prob 45.00% • Move 20.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Q2 follow-up is financially mixed but runway remains intact
2026-08-21
Q2 2026 reported no revenue and a $3.7 million net loss versus $4.8 million in Q2 2025, while cash was $14.0 million and management maintained an operating runway into the second half of 2027. An August 19 ATM sale raised approximately $1.5 million net, reducing immediate funding pressure but adding dilution risk [#IR-2026-08-20][#SEC-6K-2026-08-20].
Prob 70% • Move 4% • Priced-in 65%

Long-term Catalysts

Months to a year

Potential platform or pipeline partnership
2026-12-31
Management described several ongoing business-development discussions and said partnerships remain a key route to validating the AI-Immunology platform and supporting future development, but no transaction or timing has been announced [#IR-2026-08-20].
Prob 30% • Move 22% • Priced-in 10%

Risks

Cash declined to $14.0 million at June 30, 2026 from $23.2 million at December 31, 2025, and the company may need additional capital before commercialization [#SEC-6K-2026-08-20].
Coverage is low, peer comparability is weak, and no analyst estimate or revision tape is available.
EVX-01 three-year data may fail to demonstrate durable benefit, and future development is dependent on clinical, regulatory, manufacturing, and partnering execution.
No revenue and continuing R&D losses; Q2 2026 net loss was $3.7 million [#SEC-6K-2026-08-20].
The August 19 ATM issuance of 505,005 ADSs for approximately $1.5 million net creates dilution and ongoing financing-overhang risk [#SEC-6K-2026-08-20].

Peers

Symbol	Summary
AYTU	Loose same-sector market-cap proxy; not a direct scientific or indication peer, so useful mainly for micro-cap biotech volatility framing.
ENLV	Loose same-sector market-cap proxy; the packet provides no evidence for a direct platform comparison.
LGVN	Loose same-sector market-cap proxy; use only for broad event-risk and financing-context comparisons.
OPTH	Loose same-sector market-cap proxy with insufficient packet detail for direct operating or pipeline benchmarking.
TVRD	Loose same-sector market-cap proxy; limited comparability and no validated peer-specific operating evidence in the packet.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-21

Loading AI feed…

Symbol

Summary

AYTU

Loose same-sector market-cap proxy; not a direct scientific or indication peer, so useful mainly for micro-cap biotech volatility framing.

ENLV

Loose same-sector market-cap proxy; the packet provides no evidence for a direct platform comparison.

LGVN

Loose same-sector market-cap proxy; use only for broad event-risk and financing-context comparisons.

OPTH

Loose same-sector market-cap proxy with insufficient packet detail for direct operating or pipeline benchmarking.

TVRD

Loose same-sector market-cap proxy; limited comparability and no validated peer-specific operating evidence in the packet.